Abstract:The liver is the central metabolic organ of the body, regulating energy and lipid metabolism, while also having potent immunological functions. Overwhelming the metabolic capacity of the liver via obesity and a sedentary lifestyle leads to hepatic lipid accumulation, chronic necro-inflammation, enhanced mitochondrial/endoplasmic reticulum stress and development of non-alcoholic fatty liver disease (NAFLD), and its more severe form non-alcoholic steatohepatitis (NASH). Based on an improved understanding of pathophysiological mechanisms, specifically targeting metabolic pathways to prevent or slow down the progression of NAFLD to liver cancer will become possible. Genetic/environmental factors are also known to contribute to the development of NASH and progression to liver cancer. The complex pathophysiology of NAFLD-NASH is reflected by environmental factors, particularly the gut microbiome and its metabolic products. NAFLD-associated HCC most often occurs in the context of a chronically inflamed and cirrhotic liver. Recognition of environmental alarmins or metabolites derived from the gut microbiota and the metabolically injured liver create a strong inflammatory milieu supported by innate and adaptive immunity. Several recent studies indicate that chronic steatosis induces auto-aggressive CD8+CXCR6+PD1+ T cells that eliminate parenchymal and non-parenchymal cells in an antigen-independent manner. This promotes chronic liver damage and a pro-tumorigenic environment. CD8+CXCR6+PD1+ T cells possess an exhausted, hyperactivated, resident phenotype; they trigger the NASH to HCC transition and might be responsible for weaker responses to immune checkpoint inhibitors - in particular atezolizumab/bevacizumab. Here, we provide an overview of NASH-related inflammation/pathogenesis, focusing on new discoveries on the role of T cells. This review discusses preventive measures to halt disease progression to liver cancer and therapeutic strategies to manage patients with NASH-HCC.

Emerging role of aging in the progression of NAFLD to HCC

The Potential Role of Cellular Senescence in Non-Alcoholic Fatty Liver Disease

Hepatic NAD(+) deficiency as a therapeutic target for non-alcoholic fatty liver disease in ageing

Role of immune responses in the development of NAFLD-associated liver cancer and prospects for therapeutic modulation

Impact of Aging on Liver Cells and Liver Disease: Focus on the Biliary and Vascular Compartments

Hepatic Senescence Accompanies the Development of NAFLD in Non-Aged Mice Independently of Obesity

Role of NLRP3 Inflammasome in the Progression of NAFLD to NASH

The Role of Oxidative Stress and Cellular Senescence in the Pathogenesis of Metabolic Associated Fatty Liver Disease and Related Hepatocellular Carcinoma

Hepatic lipid metabolism and non-alcoholic fatty liver disease in aging

Lipid accumulation-induced hepatocyte senescence regulates the activation of hepatic stellate cells through the Nrf2-antioxidant response element pathway

Cellular senescence in hepatocytes contributes to metabolic disturbances in NASH

Recent advances in age-related metabolic dysfunction-associated steatotic liver disease

Roles of Long Non-coding RNAs in the Development of Aging-Related Neurodegenerative Diseases

Non-alcoholic fatty liver disease and hepatocellular carcinoma: Clinical challenges of an intriguing link

Emerging mechanisms of non-alcoholic steatohepatitis and novel drug therapies

The pivotal role of dysregulated autophagy in the progression of non-alcoholic fatty liver disease

NAFLD-Related HCC: Focus on the Latest Relevant Preclinical Models

Hepatocellular Carcinoma in Non-alcoholic Fatty Liver Disease: Current Progresses and Challenges

Aging of Liver in Its Different Diseases

Modulation of Autophagy: A Novel "Rejuvenation" Strategy for the Aging Liver

Integrative analysis of the transcriptome and metabolome reveals the importance of hepatokine FGF21 in liver aging